Sandy Douglas Lab Group’s Post

POSTCOVID-19 WAR era, (new vaccines 2019-2039) In the last/ next decades different microbial diseases will be produced (as biological weapons according to NIH subsidiary projects) i.e. viral-based COVID-19, monkeypox etc. Subsequently, all associated pharmaceutical companies (of course) have no choice but to get taxpayers' money and try to manufacture new vaccines. It is essential to understand that 1. we are living in the 21st Century and all kinds of checkups are available to test /monitor whether a mixed solution could function as a vaccine or just is a poison. 2. Simultaneously, all Pharmaceutical Company's responsibility is to check first such invitro- insitu- in vivo tests, and 3. All responsible QAs/QCs/ QMSs are guilty of charge if they don't present their QA/QC/ validating data to Authorities 4. at least but not last, ALL FDA/CDC/ NIHs' managers are guilty of charge if they don't check these data before inject into 44000 human volunteers, before 5. Make it available for social usage and inject it into ordinary people.  Take take-home message is all the abovementioned Managers are guilty of charges and should be fired if they violate Scientific and human rights, over different vaccine productions. (BBAdvies and Research internal investigation 2024)

At the height of the COVID-19 pandemic, there was one thing the world was in desperate need of: vaccines. Apprentice.io, a software company specializing in pharmaceutical manufacturing solutions, found itself with just 45 days to build a completely new platform—which spanned many different stacks as well as augmented reality headsets—to expedite vaccine delivery. No pressure though, right? Such an overhaul would have been impossible for their existing staff. Plus, software for pharma manufacturing is some of the most highly-regulated in the world — which means constant compliance audits. “To hire by ourselves organically in that timeline was going to be impossible,” explained Angelo Stracquatanio III, “There’s no way we would have been able to build what we’ve built without having a partner like A.Team.” With A.Team’s support, Apprentice.io was able to distribute 400M vaccines, raising 100M and not to mention saving countless lives. And since, they’ve already brought on 5 more A.Teams to build across all of Apprentice’s products. Need to ramp up your teams efficiency? Try Team Formation AI to see how quickly it matches your needs with A.Team’s top talent, and get an expert team deployed in days: https://hubs.la/Q02FTcW40

The ripple effects of this withdrawal could be significant. Healthcare sectors will face immediate impacts, including shifts in vaccine supply chains and potential increases in cost as providers and governments transition to alternative vaccines. This will also influence investment in pharmaceutical R&D, potentially slowing down the innovation of new treatments. Moreover, the economic implications extend beyond healthcare. For eg, insurance industries might need to adjust their risk assessments and policies regarding vaccine coverage and compensation. There could also be impacts on global travel, especially if vaccine requirements shift, affecting tourism and business travel sectors. Overall, while the direct health implications are paramount, the indirect effects on global economic stability and sectoral operations will also merit close observation as the situation unfolds. #HealthcareIndustry #EconomicImpact #VaccineConfidence

 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗵𝗮𝗿𝗲: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗿𝗼𝘀𝘀-𝗕𝗼𝗿𝗱𝗲𝗿 𝗧𝗿𝗮𝗱𝗲 🌐 As the world continues its battle against various health challenges, the spotlight remains on the pharmaceutical industry, particularly the vaccine market. Here are some key points shedding light on the market share dynamics in the global vaccine landscape: 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗗𝗼𝗺𝗶𝗻𝗮𝗻𝗰𝗲: The COVID-19 pandemic propelled vaccine development and distribution to the forefront. Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson emerged as key players, capturing significant market shares. 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁𝘀: Beyond COVID-19, vaccines for diseases like influenza, HPV, and measles continue to drive demand, especially in emerging markets. China's Sinovac and Sinopharm, along with India's Bharat Biotech, are gaining prominence with their vaccine exports to various regions. 𝗖𝗿𝗼𝘀𝘀-𝗕𝗼𝗿𝗱𝗲𝗿 𝗧𝗿𝗮𝗱𝗲 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝘀: The vaccine market is highly influenced by cross-border trade dynamics. The World Trade Organization (WTO) estimates that approximately 80% of vaccines are traded internationally, emphasizing the interconnectedness of global pharmaceutical supply chains. 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗵𝗮𝗿𝗲 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: According to recent data from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the top five vaccine manufacturers contribute to over 85% of global vaccine sales, illustrating the concentrated nature of the market. 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀: While cross-border trade facilitates access to vaccines worldwide, it also presents challenges such as supply chain disruptions and regulatory barriers. Collaborative efforts among governments, manufacturers, and international organizations are essential to address these challenges and ensure equitable vaccine distribution. 𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸: With advancements in vaccine technology and increasing focus on preventive healthcare, the global vaccine market is poised for significant growth. Strategies such as technology transfer and capacity building can further enhance cross-border trade and strengthen vaccine accessibility. Understanding the nuances of the vaccine market share within the broader context of global pharmaceutical cross-border trade is crucial for fostering collaboration and driving innovation towards a healthier, more resilient world. Let's continue the conversation on how we can collectively shape the future of healthcare through strategic partnerships and innovative solutions. #VaccineMarket #PharmaIndustry #GlobalTrade #HealthcareInnovation #CrossBorderCollaboration

This is a super interesting article by Matthew Herper in STAT. Four years after the start of the COVID-19 pandemic, the piece reflects on #pharmaceutical companies with coronavirus #vaccine programs to consider how they have faired commercially. The development of COVID-19 vaccines was a critical step in minimizing the public health burden of the pandemic. That point can’t be understated. Certainly, the most successful vaccines saved many lives, prevented a lot of misery,...and generated a lot of revenue. But, they did not all work out that way. At the same time, opting to work on COVID-19 vaccines also meant diverting resources from other drug programs. Those decisions affected longer-term prospects in the context of each company’s wider activities and pipeline. With that in mind, the article compares 5-year stock price performance for the “winners” and “losers” of the vaccine race. Though I found the list of stock prices pretty fascinating, it’s far from a complete picture. Herper does a great job summarizing each company’s development path, interlacing this discussion with commentary on other impactful events associated with each company in this time period. Anyway, I strongly recommend that you check out the entire piece below. https://lnkd.in/grNGdjDN

Pharmaceutical Innovation and Access in 2024: Advancing Health Equity Through Vaccine Distribution and Pricing Transparency In 2024, the pharmaceutical industry faces increased scrutiny regarding health equity, particularly after the COVID-19 pandemic. Companies like Pfizer and Moderna have set a precedent by prioritizing vaccine distribution to underserved communities. A WHO report highlights that low-income countries received only 20% of total vaccine doses, despite comprising 40% of the global population. To address this, major players have partnered with organizations like GAVI to enhance vaccine accessibility. Pricing strategies have become crucial in discussions about pharmaceutical innovation. The Biden administration advocates for transparency in pricing, pushing companies to disclose drug development costs. For example, Moderna initially priced its COVID-19 vaccine between $15 and $25 but committed to keeping prices low for low- and middle-income countries. As a seasoned executive with experience managing multi-million-pound projects, I can help pharmaceutical companies advance health equity. By developing partnerships with NGOs, enhancing pricing transparency, and implementing training programs for healthcare workers, I can facilitate initiatives that improve access to medications in underserved areas. In conclusion, pharmaceutical companies must navigate innovation, equity, and access to ensure that the benefits of advancements reach every corner of the globe. References World Health Organization. (2021). COVID-19 Vaccine Access and Distribution. WHO Report. Global Vaccine Alliance (GAVI). (2022). Global Vaccine Distribution Efforts. GAVI Report. Pfizer. (2023). Equity in Vaccine Distribution. Pfizer Insights. Biden Administration. (2023). Pharmaceutical Pricing Reforms. White House Press Release. The New York Times. (2023). Transparency in Drug Pricing. NYT Article. Moderna. (2023). Vaccine Pricing Commitment. Moderna Updates. Forbes. (2024). Concerns Over Vaccine Pricing. Forbes Article. Deloitte. (2023). Consumer Perspectives on Pharmaceutical Access. Deloitte Report. Hashtags #PharmaceuticalInnovation #HealthEquity #VaccineDistribution #PricingTransparency #Pfizer #Moderna #COVID19 #GlobalHealth #HealthcareAccess #GAVI #PublicHealth #BidenAdministration #TransparencyInHealthcare #Deloitte #WHO #VaccineAccess #HealthForAll

Scendea's award-winning team have extensive US & EU experience supporting the development of a wide range of vaccines. Book an exploratory call with our team to understand how we can support your vaccine development: www.scendea.com/contact - Our latest whitepaper 'Therapeutic Vaccines – Regulatory Challenges for Non-Clinical Development' written by Stephen Kirk, Principal Consultant, provides valuable insights into the regulatory challenges and non-clinical development requirements for therapeutic vaccines. Read and download the full paper here: https://lnkd.in/gnchc3X9 - #drugdevelopment #regulatorysupport #vaccines

𝗧𝘆𝗽𝗵𝗼𝗶𝗱 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 This research report provides a comprehensive analysis of the Typhoid Vaccine industry chain, detailing the market status across hospitals (Oral Type Typhoid Vaccine, Injection Type Typhoid Vaccine) and research & academic laboratories (Oral Type Typhoid Vaccine, Injection Type Typhoid Vaccine), along with profiles of key enterprises in both developed and developing markets. It examines cutting-edge technology, patents, hot applications, and market trends. Regionally, the report focuses on key areas, noting steady growth in North America and Europe driven by government initiatives and increasing consumer awareness, while Asia-Pacific, particularly China, leads the global market due to robust domestic demand, supportive policies, and a strong manufacturing base. The Typhoid Vaccine market is segmented by type and application, with forecasts from 2024 to 2031 providing accurate calculations and projections for consumption value by type and application in terms of volume and value, aiding in the identification and targeting of promising niche markets. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗧𝘆𝗽𝗵𝗼𝗶𝗱 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/d-XZ5mZB *𝗕𝘆 𝗧𝘆𝗽𝗲: Oral Type Typhoid Vaccine, Injection Type Typhoid Vaccine *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Sanofi, Merck, GSK, Actiza Pharmaceutical Pvt. Ltd., Merit Pharmaceuticals, Bharat Biotech #typhoidvaccine #vaccination #publichealth #infectiousdiseases #healthcare #globalhealth #immunization #vaccineawareness #typhoidfever #medicalresearch #preventivemedicine #health #vaccine #medicalinnovation #diseaseprevention #healthtech #travelmedicine #vaccineefficacy #healthyliving #vaccinesafety #medicalscience #vaccineimpact #healthprotection #healthcareinnovation #vaccineeducation #publichealthawareness

At Extreme Investor Network, we strive to bring you the latest and most impactful information in the world of economics. Today, we want to discuss a recent development that has shaken the pharmaceutical industry and raised serious concerns about COVID-19 vaccines. #Armstrong #AstraZeneca #covid #distribution #economics #Halts #Vaccine

Pharmaceutical giant AstraZeneca has announced the global withdrawal of its Covid-19 vaccine, Vaxzevria, citing a surplus of newer vaccine options as the primary reason. The company has voluntarily withdrawn the "marketing authorization" for the vaccine within the European Union, and similar applications are expected to be made in other countries where the vaccine was approved. The decision comes amidst ongoing legal battles faced by AstraZeneca over allegations that its vaccine, developed in collaboration with the University of Oxford, led to fatalities and severe injuries, including Thrombosis with Thrombocytopenia Syndrome (TTS). #AstraZeneca #astrazenecanews #vaccinenews #WorldNews #pharmaceuticals #pharmaceuticalindustry #COVID19 #coronavirus #vaccine #VaccineSideEffects #withdrawal #TTS #trendingnews #viralnews #virals #healthandwellness